In addition, increased serum IgA and IgM concentrations against bacterial LPS have been detected in patients with severe ME/CFS, and BCR-seq studies, representing the genetic basis for antibody binding, have indicated differences in patients with severe ME/CFS compared to healthy individuals (44, 45). The gene discussed is CD79A; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.